Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
OCGN | US
-0.03
-2.19%
Healthcare
Biotechnology
30/06/2024
02/06/2026
1.34
1.37
1.38
1.33
Ocugen Inc. a clinical-stage biopharmaceutical company focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400 a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases such as retinitis pigmentosa and leber congenital amaurosis; OCU410 and OCU410ST for the treatment of dry age-related macular degeneration (AMD); and OCU200 a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema diabetic retinopathy and wet AMD. It has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern Pennsylvania.
View LessLow Debt to Asset (< 0.2)
Strong Revenue Growth (> 10%)
Price Below SMA10D
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
39.2%1 month
77.6%3 months
97.1%6 months
90.8%-
15.22
15.82
0.41
0.17
-1.95
35.65
-
-50.51M
385.73M
385.73M
-
-1.35K
-
135.30
-114.42
13.03
17.89
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0.16
Range1M
0.63
Range3M
1.45
Rel. volume
0.54
Price X volume
5.84M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Enzon Pharmaceuticals Inc | ENZN | Biotechnology | 5.95 | 424.25M | -0.83% | 12.00 | 0.00% |
| Sensei Biotherapeutics Inc | SNSE | Biotechnology | 16.095 | 404.81M | -18.67% | n/a | 9.67% |
| Regulus Resources Inc | RGLSF | Biotechnology | 3.17 | 397.80M | 0.00% | n/a | 0.00% |
| KEROS THERAPEUTICS INC. | KROS | Biotechnology | 10.55 | 395.86M | -3.21% | n/a | 3.32% |
| Kazia Therapeutics Limited | KZIA | Biotechnology | 11.79 | 392.43M | -6.13% | n/a | 6.82% |
| Evolus Inc | EOLS | Drug Manufacturers-Specialty & Generic | 6.17 | 389.29M | -5.37% | n/a | 656.27% |
| PASSAGE BIO INC. | PASG | Biotechnology | 5.895 | 364.12M | 0.77% | n/a | 28.88% |
| Aviragen Therapeutics Inc | AVIR | Biotechnology | 4.27 | 360.48M | -2.51% | n/a | 0.43% |
| Xilio Therapeutics Inc. Common Stock | XLO | Biotechnology | 8.2 | 360.41M | -0.61% | n/a | 25.98% |
| Aquestive Therapeutics Inc | AQST | Drug Manufacturers-Specialty & Generic | 3.93 | 357.87M | -1.75% | n/a | -329.45% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| MCBC Holdings Inc | MCFT | Recreational Vehicles | 23.21 | 385.46M | -0.04% | 34.27 | 26.82% |
| ACCO Brands Corporation | ACCO | Building Products & Equipment | 3.88 | 371.70M | -0.77% | n/a | 174.23% |
| Camping World Holdings Inc | CWH | Recreational Vehicles | 7.44 | 335.76M | -1.06% | n/a | 3644.76% |
| Urban One Inc | UONEK | Broadcasting - Radio | 4.7 | 249.14M | -10.36% | n/a | 268.43% |
| CPI Card Group Inc | PMTS | Building Products & Equipment | 16.74 | 186.78M | -0.42% | 15.61 | -621.78% |
| ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 11.36 | 182.41M | 2.53% | n/a | 286.96% |
| Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 40.57 | 116.51M | -0.44% | 5.16 | 19.82% |
| Virco Mfg. Corporation | VIRC | Building Products & Equipment | 6.01 | 97.90M | 0.84% | 9.09 | 39.79% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 7.09 | 67.49M | 2.75% | n/a | 19.98% |
| ILAG | ILAG | Building Products & Equipment | 3.6016 | 65.04M | -4.21% | n/a | 5.48% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -1.95 | 0.53 | Cheaper |
| Ent. to Revenue | 35.65 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 15.82 | 15.55 | Par |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 97.06 | 72.80 | Riskier |
| Debt to Equity | 0.41 | -1.23 | Expensive |
| Debt to Assets | 0.17 | 0.25 | Cheaper |
| Market Cap | 385.73M | 3.66B | Emerging |